Friday, August 21, 2015

ePharma news: This August - The Ice Bucket Challenge is back | "Viagra" for women is about to hit the market and more

Pin It Now!
The ALS Ice Bucket Challenge is back with the hashtag #EveryAugustUntilACure
Do you remember the Ice Bucket Challenge that took over the world last year? A brilliant campaign that was initiated by ALS Association in hopes to raise money for the Lou Gehrig's disease research, went viral not just in the U.S. but globally as well. By the end of 2014 the ALS Association was able to raise $115 million dollars. This August the Ice Bucket Challenge is back, and the funds collected last year are partially allocated toward the Lou Gehrig's disease research project conducted by Biogen Inc. and the Columbia University Medical Center. Earlier this year Biogen announced a $30-million-dollars funding that the company has committed to (plus, $3.5 million dollars raised by the Ice Bucket Challenge promotion.) The project is said to monitor 1,500 patients with the disease through clinical trial in efforts to find the cure.

Addyi is a "female version" of the Viagra pill produced by Sprout Pharmaceuticals
A "female version" of Viagra has just been approved by the FDA. Addyi is the first of its kind drug aiming at treatment of sexual desire disorders (HSDD) in both genders. HSDD stands for hypoactive sexual desire disorder, and as stated on the FDA official page: "HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. HSDD is acquired when it develops in a patient who previously had no problems with sexual desire." It's noteworthy that the drug manufacturer Sprout Pharmaceuticals has been previously turned down twice, because the benefits of Addyi were said to be outweighed by the side effects and the risks caused by taking the drug. The Addyi drug has been approved with a strong warning against taking it with alcohol and other drugs because of its potentially toxic effect on the organism, and it will only be available through certified medical professionals. 

This week Kite Pharma is on a news but unfortunately not for a break through research but because of one of the patient's death while in a blood cancer clinical trial. The LA Times reported, that during the conference call the Kite Pharma CEO Arie S. Belldegrun stated, "A clinical investigator of the study conducted an in-depth review of the death and concluded that this death was unrelated to our product."
Following the investigation the FDA allowed the Kita Pharma company to continue with clinical trials.

Bionic wearable-technology earbuds Here Active Listening from Dobbler Labs
Image courtesy: http://www.hereplus.me/
Earbuds that will turn down the noise volume around you including the sound of crying babies? - Yes, please! A wearable-technology startup Doppler Labs has invented a wireless earbuds device that aims at increasing and adjusting your hearing depending on your personal comfort level. With the mission "Change the Way We Hear the World" and the price tag of $199, Here Active Listening is targeting audiophiles first. The company has posted a testimony-video by Hans Zimmer, a world-famous Grammy-winning composer, who in his support to the Here Active Listening gadget stated, "The way we find our place in the world is through touch, eyes, and hugely - through ears. You want to be able to select what you hear. It's about having control of your life."


Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Post a Comment